Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aztreonam

FDA-approved product (injectable, injection), marketed as Azactam, Azactam In Plastic Container, Aztreonam and 1 more.

Registered studies
50+
Lab records
165
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Aztreonam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Cystic fibrosis
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Monobactams
FDA pharmacologic class
Monobactam Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DF01; FDA class Monobactam Antibacterial

Repurposing investigation

Aztreonam is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli97.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 34 of 161 lab records
Open Aztreonam in ChEMBL Registered studies below
Show the latest 150 of 165 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aztreonam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

    NCT00112359 · start 2005-05

    Registered record
    Registry ID
    NCT00112359
    Conditions
    Cystic Fibrosis
    Interventions
    AZLI 75 mg three times a day (TID); Placebo three times a day (TID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-05
    Completion
    2007-04
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionAZLI 75 mg three times a day (TID); Placebo three times a day (TID)
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

    NCT00104520 · start 2005-02

    Registered record
    Registry ID
    NCT00104520
    Conditions
    Cystic Fibrosis
    Interventions
    AZLI 75 mg two times a day (BID)/three times a day (TID); Placebo two times a day (BID)/three times a day (TID)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2006-09
    Enrolment
    211

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionAZLI 75 mg two times a day (BID)/three times a day (TID); Placebo two times a day (BID)/three times a day (TID)
    PhasePhase 3
    Registry statusCompleted

  • Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections

    NCT00228410 · start 2002-11

    Registered record
    Registry ID
    NCT00228410
    Conditions
    Skin Diseases, Infectious
    Interventions
    Tigecycline; vancomycin with aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-11
    Completion
    2003-12
    Enrolment
    503

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious
    InterventionTigecycline; vancomycin with aztreonam
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

    NCT00035425 · start 2001-11

    Registered record
    Registry ID
    NCT00035425
    Conditions
    Febrile Neutropenia
    Interventions
    linezolid; vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2002-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    Interventionlinezolid; vancomycin
    PhasePhase 3
    Registry statusCompleted

  • Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

    NCT00989807

    Registered record
    Registry ID
    NCT00989807
    Conditions
    Cystic Fibrosis; Pseudomonas Aeruginosa
    Interventions
    Aztreonam lysine
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pseudomonas Aeruginosa
    InterventionAztreonam lysine
    PhaseNot recorded
    Registry statusApproved for marketing